The effect of supplemental whey protein timing on postprandial glycaemia in centrally obese males by Allerton, Dean et al.
Northumbria Research Link
Citation:  Allerton,  Dean, Rumbold,  Penny, West,  Dan and Stevenson, Emma (2019) The effect of 
supplemental whey protein timing on postprandial glycaemia in centrally obese males. British Journal 
of Nutrition, 121 (6). pp. 637-646. ISSN 0007-1145 
Published by: Cambridge University Press
URL: https://doi.org/10.1017/S0007114518003793 <https://doi.org/10.1017/S0007114518003793>
This version was downloaded from Northumbria Research Link: http://nrl.northumbria.ac.uk/37420/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)
                        
Accepted manuscript 
1 
 
The effect of supplemental whey protein timing on postprandial glycaemia in 1 
centrally-obese males 2 
 3 
 4 
Dean M. Allerton1, Penny L. S. Rumbold2, Daniel J. West3, Emma J. Stevenson3 5 
 6 
1 School of Biomedical Sciences, Newcastle University, Newcastle upon Tyne, UK. 7 
2 Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK. 8 
3 Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, 9 
Newcastle upon Tyne, UK. 10 
 11 
 12 
 13 
Running title: Whey protein timing and glycaemia 14 
 15 
 16 
Corresponding author:  17 
Professor Emma Stevenson 18 
Institute of Cellular Medicine, 19 
Newcastle University,  20 
Newcastle upon Tyne,  21 
NE2 4HH,  22 
UK. 23 
 24 
Tel: 0191 208 7865 25 
Email: emma.stevenson@newcastle.ac.uk  26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
This peer-reviewed article has been accepted for publication but not yet copyedited or 
typeset, and so may be subject to change during the production process. The article is 
considered published and may be cited using its DOI. 
10.1017/S0007114518003793 
:DD$C,*** 53!4%697 #%95#%7D7%!C :DD$C,6# #%9 1	

.#*" #36768%#!:DD$C,*** 53!4%697 #%95#%7 2")7%CD+#8/6"4E%9:04%3%+#".753D,	,CE475DD#D:73!4%697#%7D7%!C#8EC73)3 34 73D
Accepted manuscript 
2 
 
Key words: x Whey protein x Postprandial x Glucose x Insulin x Appetite 34 
ABSTRACT 35 
 36 
Consuming whey protein prior to a meal may reduce postprandial glucose excursions, however 37 
optimising timing of supplementation is important to improve its clinical utility. Thirteen centrally-38 
obese, insulin resistant males (waist circumference: 121 (SEM 3) cm; HOMA-IR: 6.4 (SEM 1.2)) 39 
completed four experimental conditions in a single-blind, crossover design. Participants consumed 40 
mixed-macronutrient breakfast and lunch meals on all occasions, with 20 g whey protein consumed 41 
15 min prior to (PRE), alongside (DUR) or 15 min post-breakfast (POST), or omitted (CON). 42 
Capillary glucose and plasma concentrations of insulin, triglycerides and NEFA, in addition to 43 
subjective appetite ratings, were collected for 180 min after each meal. PRE and DUR reduced post-44 
breakfast glucose peak by 17.0 (SEM 1.9)% (P < 0.001) and 9.2 (SEM 2.9)% (P = 0.046) respectively, 45 
compared with CON. Post-breakfast glucose AUC was lower following PRE compared with POST 46 
and CON (PRE: 982 (SEM 30) vs POST: 1031 (SEM 36) and CON: 1065 (SEM 37) mmol/l x 180 min; 47 
P ≤ 0.042), but similar to DUR (1013 (SEM 32) mmol/l x 180 min; P = 0.77). Insulin was lower 48 
during PRE, when compared with POST and DUR (both P ≤ 0.042), but similar to CON. There 49 
were no between-condition differences in measures of postprandial lipaemia or appetite, and no 50 
effect of condition post-lunch. Consumption of whey protein as a preload or alongside a mixed-51 
macronutrient breakfast reduces postprandial glucose excursions in centrally-obese, insulin resistant 52 
males. Whey consumed as a preload has superior glycaemic lowering effects. Supplementation at 53 
breakfast does not alter glycaemic responses to subsequent meals.  54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
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 68 
INTRODUCTION 69 
 70 
Central obesity is associated with insulin resistance and an increased risk of developing type 2 71 
diabetes and cardiovascular disease 1,2. In those without diagnosed type 2 diabetes, postprandial 72 
glucose excursions are a stronger predictor of HbA1c than fasting glucose, and also increase the risk 73 
of cardiovascular disease 3-5. Postprandial hyperglycaemia, no matter how brief, drives 74 
inflammation, oxidative stress and vascular dysfunction 6-9. Thus, individuals who are centrally-75 
obese and insulin resistant may benefit from strategies that ameliorate postprandial hyperglycaemic 76 
excursions 10.  77 
 78 
Recent non-pharmaceutical interventional studies have sought to reduce postprandial 79 
hyperglycaemia through whey protein supplementation (for review 11). Whey protein contains an 80 
abundant source of amino acids and bioactive peptides that are rapidly digested. These act as potent 81 
insulin secretagogues and can reduce gastric emptying, hepatic glucose production, and can increase 82 
satiety 12-16. Despite many trials in normal-weight populations or individuals with type 2 diabetes, 83 
few studies have been conducted using centrally-obese participants without metabolic disease. This 84 
is surprising given that such individuals are likely to be exposed to elevated postprandial glycaemic 85 
excursions 17 and their associated adverse metabolic effects 18. 86 
 87 
There are practical limitations associated with implementing pre-meal whey protein as a strategy to 88 
reduce postprandial hyperglycaemia. Firstly, studies have investigated the glycaemic response to 89 
single test meals of primarily high glycaemic index carbohydrate content 19,20, without investigating 90 
if the whey supplementation effects carry forward to subsequent meals. Secondly, dosages of whey 91 
protein administered are generally unrealistically large (45-55 g; ~200 kcal) 19,21. Furthermore, 92 
whey protein has shown most benefit when supplemented as a preload around 30 min before the 93 
main meal 19,22, thus restricting its ecological validity when applied in free-living conditions, as this 94 
does not reflect conventional eating habits 23. From a clinical viewpoint it is important to establish 95 
whether the beneficial effect of whey supplementation is retained at smaller doses, if the whey 96 
bolus is beneficial when consumed alongside or after the meal, and if the therapeutic effects 97 
influence glycaemia at subsequent meal times in centrally-obese insulin resistant individuals.  98 
 99 
The purpose of this study was to investigate the effect of a realistic whey protein dose on 100 
postprandial metabolic and appetite responses in centrally-obese insulin resistant individuals, using 101 
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timings and test meals that reflect habitual eating behaviours. We hypothesise that whey protein 102 
consumption will reduce the postprandial glucose response and positively affect subjective appetite, 103 
with more favourable effects resulting from earlier supplementation. 104 
 105 
 106 
METHODS 107 
 108 
Participants 109 
 110 
Centrally-obese male participants, free from metabolic disease, were recruited from the local 111 
community. Participants who met the inclusion criteria for gender (male), age (18-55 years), waist 112 
circumference (>102 cm) and physical activity level (low) were included in the study (n = 13; see 113 
Table 1 for participant characteristics). The waist circumference criterion value was based on the 114 
WHO threshold associated with the greatest risk of metabolic complications in males 24. This was 115 
measured at the mid-point between the lower costal border and the illiocristale, according to 116 
International Society for the Advancement of Kinanthropometry (ISAK) guidelines 25. Physical 117 
activity level was assessed using the categorical scoring method following completion of the 118 
International Physical Activity Questionnaire 26.  119 
 120 
Ethical approval 121 
 122 
This study was conducted according to the guidelines laid down in the Declaration of Helsinki and 123 
all procedures were approved by the Faculty of Health and Life Sciences Research Ethics 124 
Committee (reference: HLSDA020415). All participants provided prior written informed consent. 125 
This study was registered at clinicaltrials.gov (NCT02658110). 126 
 127 
Study design 128 
 129 
Participants completed four experimental conditions in a randomised order, as part of a single-blind, 130 
crossover design. Each condition was separated by at least 3 days. On all visits participants 131 
consumed a standardised mixed-macronutrient breakfast meal, followed 180 min later by 132 
consumption of a standard lunch meal. The timing of additional protein supplementation varied by 133 
condition, with participants consuming 20 g whey protein as a preload 15 min prior to breakfast 134 
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(PRE), during the breakfast meal (DUR), or 15 min post-breakfast consumption (POST). A control 135 
condition was also completed without additional protein supplementation (CON).  136 
 137 
Pre-trial standardisation 138 
 139 
Prior to each experimental visit participants were provided with verbal and written instructions 140 
regarding diet and physical activity control measures. For 24 hours prior to arrival participants were 141 
instructed to avoid caffeine and alcohol consumption as well as strenuous physical activity. A 142 
mixed-macronutrient meal was provided before each visit (3501 kJ; 37/19/44% energy from 143 
carbohydrate/protein/fat), and participants were instructed to consume this as their evening meal 12 144 
hours prior to their arrival time, in order to standardise macronutrient and energy intake.  145 
 146 
Experimental protocol 147 
 148 
The experimental protocol is presented in Figure 1. Participants arrived at the laboratory at the same 149 
time (~08.00 hours) on each occasion following an overnight fast. After insertion of a cannula in an 150 
antecubital vein, baseline venous and capillary blood samples were collected and subjective appetite 151 
was assessed using visual analogue scales. In the PRE condition, participants consumed a 20 g 152 
whey protein beverage, with flavoured water (placebo) provided in all other conditions. After a 153 
further 15 min, breakfast was consumed in all conditions, accompanied by either a whey protein 154 
(DUR) or placebo test drink (POST and CON). At 15 min post-breakfast consumption, a further test 155 
drink was provided, with whey protein administered in the POST condition and flavoured water 156 
during all other conditions. The remainder of the protocol was identical under all experimental 157 
conditions, with blood samples and appetite ratings collected at regular intervals (Figure 1). 158 
Participants rested in a seated position for 180 min following breakfast consumption, after which a 159 
standardised lunch meal was consumed. Following a further period of seated rest (180 min), the 160 
cannula was removed and participants were able to leave the laboratory.  161 
 162 
Test meals 163 
 164 
At each test drink time point (15 min before, during or 15 min after breakfast) either a whey protein 165 
or placebo drink was consumed which was condition-dependent. The protein drink contained 23g 166 
whey protein isolate powder (Lacprodan SP-9225 Instant; Arla Food Ingredients Group, Viby, 167 
Denmark) mixed with 150 ml water and 0.5 ml energy-free strawberry flavouring (FlavDrops, 168 
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Myprotein, UK), providing 20 g protein (87% protein content) and 343 kJ (82 kcal) energy. The 169 
placebo drink was matched for volume and taste using similarly flavoured water. All drinks were 170 
provided in opaque bottles and no reference was made to which condition was being conducted. An 171 
additional 200 ml drinking water was administered after each test beverage to eliminate any after 172 
taste.  173 
 174 
A standardised breakfast of rolled oats (54.0 g) with semi-skimmed milk (260 ml) and honey (42.5 175 
g) was provided under all conditions as a semi-liquid porridge mixture. This provided 1958 kJ (468 176 
kcal) of energy (70% carbohydrate, 17% fat, 13% protein). Participants were encouraged to 177 
consume this meal within 10 min. Porridge was selected to represent a habitually consumed 178 
breakfast food amongst the UK population 27 which provides a mixed macronutrient composition.  179 
 180 
A standardised mixed-macronutrient lunch meal was provided in all conditions, as described 181 
previously 28. A 125 g portion of dried fusilli pasta was cooked and combined with 170 g of a 182 
tomato-based sauce (Dolmio, Mars, USA), grated cheddar cheese (40 g) and olive oil (15 g). The 183 
resulting homogenous meal provided 3448 kJ (824 kcal) of energy (50% carbohydrate, 36% fat, 184 
14% protein). Participants were again instructed to finish the entire meal within 10 min. Water 185 
(500 ml) was also served alongside the lunch meal, and was withheld in the post-lunch period.  186 
 187 
Blood sampling and analysis 188 
 189 
On arrival, a cannula (Vasofix 22G, B.Braun Melsungen AG, Germany) was inserted into a vein in 190 
the antecubital fossa while participants remained in a semi-supine position. At each sample point, 191 
10 ml of whole venous blood was drawn into a syringe and transferred into an EDTA coated tube 192 
(Vacutainer, Becton Dickinson, USA) followed by centrifugation at 1734 g and 4˚C for 10 min 193 
(Allegra X-22R, Beckman Coulter, USA). Plasma was aliquoted into separate microtubes and 194 
stored at -80˚C for subsequent analysis. Sterile stylets (22G, B.Braun Melsungen AG, Germany) 195 
were inserted to keep the cannula patent between blood samples. To control for any postural 196 
changes in plasma volume participants were instructed to remain in a seated position throughout the 197 
protocol where possible. 198 
 199 
Capillary blood samples (20 µl) were collected immediately following each venous blood draw 200 
using the finger-prick technique and processed for glucose (Biosen C_line analyser, EKF 201 
Diagnostics, UK). Additional samples were collected at 5 and 10 min post-meal in order to increase 202 
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the resolution of the blood glucose curve during the period where rapid changes may occur. Venous 203 
samples were processed and analysed for concentrations of plasma insulin, NEFA and triglyceride. 204 
Insulin concentrations were determined using a commercially available ELISA (IBL International, 205 
Hamburg, Germany), with intra and inter-assay variation (CV) of 5.9% and 8.9% respectively. 206 
NEFA and triglyceride concentrations were determined by enzymatic colorimetric assays using an 207 
automated analyser (RX Daytona, Randox Laboratories, UK) according to manufacturer 208 
instructions.  209 
 210 
Subjective appetite 211 
 212 
Subjective ratings of appetite were captured at baseline and at regular intervals throughout (Figure 213 
1). The reproducibility of within-subject responses and the sensitivity to experimental 214 
manipulations for this technique have previously been established  29. Paper-based 100 mm scales 215 
were used to record perceptions of hunger, fullness, satisfaction and prospective food consumption 216 
(PFC).  217 
 218 
Statistical analysis 219 
 220 
A sample size calculation was performed using a reduction in postprandial glycaemia (AUC) as the 221 
primary outcome. Based on the observed 16% reduction in glucose AUC following consumption of 222 
whey protein with a mixed-macronutrient breakfast in an overweight/obese population 30, it was 223 
calculated that a sample size of 11 would provide statistical power above 80%, with a two-sided 224 
alpha level of 0.05. To account for a 20% dropout, a minimum of 13 participants was targeted.  225 
 226 
Serial measures of blood analytes and subjective appetite responses were used to calculate AUC 227 
using the trapezoidal method. The resultant total AUC includes all area below the response curve in 228 
order to take account of situations where concentrations fell below baseline 31. Insulin sensitivity 229 
was assessed using the Matsuda Insulin Sensitivity Index (ISI), calculated using fasting and 230 
postprandial concentrations of plasma glucose and plasma insulin 32. A combined appetite score 231 
(CAS), was used to combine the four aspects of subjective appetite assessment, as described 232 
previously 33.  233 
 234 
Statistical analysis was conducted using SPSS (version 21, IBM, USA). Blood and plasma analyte 235 
concentrations and subjective appetite responses were tested for differences between conditions 236 
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over time using two-way (condition x time) repeated measures ANOVA. Area under the curve was 237 
analysed using one-way ANOVA. Post hoc analysis was performed upon identification of 238 
significant main effects and the Bonferroni correction was used to correct the level of alpha for 239 
multiple comparisons. The level of statistical significance was set at p < 0.05 and data are presented 240 
as mean values with their standard errors. 241 
 242 
 243 
RESULTS 244 
 245 
Post-breakfast responses 246 
 247 
Fasting values did not differ between conditions for all physiological and appetite variables 248 
assessed (P > 0.05). Blood glucose responses displayed a significant condition x time interaction 249 
effect (P < 0.001) in addition to main effects of condition (P < 0.001) and time (P < 0.001). Glucose 250 
peaked at 30 min post-breakfast under all conditions (Figure 2a), with the magnitude of the peak 251 
significantly reduced when whey protein was consumed as a preload or alongside breakfast 252 
compared with whey after the meal or no supplementation (PRE: 7.2 (SEM 0.3), DUR: 7.8 (SEM 0.3) 253 
vs POST: 8.6 (SEM 0.3), CON: 8.6 (SEM 0.2) mmol/l; all P ≤ 0.046). A tendency for peak glucose to 254 
be reduced in PRE compared to DUR was also observed, however this was not statistically 255 
significant (P = 0.076). Compared to CON, glucose was lower in PRE at 10-45 min (P ≤ 0.017), 256 
and in DUR at 30-60 min post-breakfast (P ≤ 0.041). Concentrations returned to baseline levels 257 
under all conditions thereafter (P > 0.05). Glycaemia across the post-breakfast period was 258 
significantly lower following whey preload compared with POST and CON conditions (AUC: PRE: 259 
982 (SEM 30) vs POST: 1031 (SEM 36) and CON: 1065 (SEM 37) mmol/l x 180 min; P ≤ 0.042), but 260 
not significantly different from the whey with meal condition (DUR: 1013 (SEM 32) mmol/l x 180 261 
min; P = 0.77; Figure 2b). Glycaemia was not significantly different from CON when whey was 262 
supplemented during (P = 0.171) or after (P = 0.816) the breakfast meal. 263 
 264 
Postprandial plasma insulin concentrations displayed significant effects of time (P < 0.001) and 265 
significant condition x time interactions (P = 0.008; Figure 2c). At the time of breakfast 266 
consumption (0 min) insulin was elevated in PRE compared to CON (P = 0.04). Concentrations 267 
rose following breakfast consumption, remaining significantly elevated above baseline level at all 268 
time points between 15 and 120 min post-breakfast (P ≤ 0.007; Figure 2c). Insulin AUC across this 269 
period showed a reduced insulin response when whey was supplemented before breakfast compared 270 
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with other supplementation times (AUC: PRE: 96340 (SEM 10807) vs DUR: 112344 (SEM 10310) 271 
and POST: 121997 (SEM 15862) pmol/l x 180 min; P ≤ 0.032; Figure 2d), and was similar to the 272 
response following breakfast without additional protein (CON: 99115 (SEM 14656) pmol/l x 180 273 
min; P > 0.05). When whey was supplemented after the meal, insulinaemia was ~23% greater than 274 
CON (P = 0.049). Insulin sensitivity did not significantly differ between conditions during the post-275 
breakfast period (Matsuda-ISI; PRE: 3.8 (SEM 0.6), DUR: 2.9 (SEM 0.5), POST: 2.8 (SEM 0.4), CON: 276 
3.3 (SEM 0.5) arbitrary units; P = 0.161).  277 
 278 
Post-breakfast NEFA concentrations were significantly affected by time (P < 0.001) such that 279 
concentrations were immediately suppressed following breakfast consumption under all conditions, 280 
and remained significantly below baseline from 15-180 min post-breakfast (P ≤ 0.006; Figure 2e). 281 
There was no effect of condition (P = 0.611) and NEFA AUC was similar between conditions 282 
across this period (P = 0.517; Figure 2f).  283 
 284 
An effect of time (P < 0.001), but not condition (P = 0.26) or condition x time interaction 285 
(P = 0.423), was observed on appetite perceptions following breakfast. Combined appetite ratings 286 
were similarly suppressed under all conditions following breakfast consumption, reaching their 287 
nadir at 15-30 min post-consumption, the magnitude of which was not different between conditions 288 
(PRE: 14  (SEM  4), DUR: 15  (SEM  4), POST: 17  (SEM  4), CON: 20  (SEM  4) mm; P = 0.344; Figure 289 
3a). Appetite subsequently increased gradually, reaching similar levels to baseline at 120-180 min 290 
post-breakfast in all conditions (P > 0.05). There were no significant differences in AUC between 291 
conditions for combined appetite score (Figure 3b) or individual subjective appetite components 292 
across this period (P > 0.05; Table 2).  293 
 294 
Post-lunch responses 295 
 296 
Following consumption of a standardised lunch meal, both glucose and insulin concentrations 297 
displayed a significant effect of time (P < 0.001), with no condition x time interactions observed 298 
(P > 0.05). Concentrations peaked similarly across all conditions before returning to pre-lunch 299 
levels at 60 and 90 min post-lunch for glucose and insulin respectively (Figure 4). Post-lunch AUC 300 
revealed no differences between conditions in glycaemia (P = 0.262) or insulinaemia (P = 0.271; 301 
Figure 4).  302 
 303 
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Post-lunch NEFA concentrations were not influenced by condition (P = 0.346), with similar AUC 304 
observed between conditions (P = 0.587; Figure 4f). Concentrations were moderately suppressed at 305 
45-60 min post-lunch under all conditions, before returning to pre-lunch levels at 90-180 min 306 
(Figure 4e). Appetite was similarly affected by consumption of lunch in all conditions (P = 0.423). 307 
An effect of time was present (P < 0.001), such that there was an immediate reduction in combined 308 
appetite score following lunch, before gradually returning to pre-lunch levels at 150-180 min post-309 
consumption across all conditions (Figure 3c). There were no significant differences observed in 310 
post-lunch AUC for combined appetite score (Figure 3d) or its constituent components of hunger, 311 
fullness, PFC and satisfaction between conditions (P > 0.05; Table 2). 312 
 313 
Plasma triglyceride 314 
 315 
Triglyceride concentrations increased similarly over the course of the experimental protocol in all 316 
conditions. Post hoc analysis of the main effect of time (P < 0.001) indicated that levels were 317 
elevated above baseline concentration from 60 min post-breakfast onwards (P ≤ 0.018), and 318 
continued to rise throughout (Figure 5a). There was no effect of condition on triglyceride 319 
concentrations (P = 0.653), and AUC was similar between conditions for triglyceride response 320 
across the full postprandial period (P = 0.64; Figure 5b).  321 
 322 
 323 
DISCUSSION 324 
 325 
The findings of the current study demonstrate that consumption of a 20 g whey protein bolus, either 326 
before or alongside a mixed-macronutrient breakfast, attenuates peak postprandial glucose 327 
excursions in centrally-obese, insulin resistant males. Furthermore, consuming whey as a preload 328 
appears to confer the greatest beneficial effect to reducing postprandial hyperglycaemia. Moreover, 329 
post-meal whey protein consumption raises insulinaemia but without a concomitant reduction of 330 
hyperglycaemia. The beneficial effects of prandial whey protein supplementation are acute, and do 331 
not carry forward to subsequent meals.   332 
 333 
Peak glucose excursions and glucose area under the curve were reduced when whey was 334 
supplemented as a preload or with the meal. Postprandial hyperglycaemia is a greater risk factor for 335 
CVD than increased fasting glucose in non-diabetics 3,4, where its contribution to overall glycaemia 336 
is particularly marked. Furthermore, postprandial glycaemic excursions have been established as the 337 
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main causative factor in glycaemic variability in non-insulin treated individuals with impaired 338 
glucose tolerance 34, and such excursions manifest adverse metabolic effects via activation of 339 
oxidative stress and endothelial dysfunction 35. Thus, evidence supports recommending reductions 340 
in postprandial hyperglycaemia as a relevant clinical goal in delaying or preventing the onset of 341 
type 2 diabetes 36. Our data show that a moderate 20 g dose of whey protein offers practical utility 342 
as a meal-time aid for reducing the hyperglycaemic burden, with a post-breakfast reduction in peak 343 
glucose of 17.0% and 9.2% when whey was consumed before or alongside the meal respectively. 344 
Additionally, a 7.3% decrease in glucose AUC across the postprandial period was observed 345 
following the whey preload, devoid of any significant change in insulin AUC. Whilst it is 346 
understood that postprandial hyperglycaemia is predictive of various complications and metabolic 347 
derangements, as described above, the clinical significance of such a reduction in glucose AUC of 348 
the magnitude shown in our study, in terms of translation to a clinical end point, remains unclear.  349 
 350 
The mechanisms explaining the reduction in postprandial glycaemia are yet to be fully elucidated. 351 
Our data contrast with prior literature 19,21, in that the insulin concentrations were not elevated 352 
during the postprandial period with the preload supplementation strategy. However, at the onset of 353 
the breakfast ingestion, we observed raised insulin concentrations under PRE in comparison to 354 
CON (Figure 2). A reduction in the early postprandial insulin response to feeding is a characteristic 355 
associated with insulin resistance and type 2 diabetes 37, and thus the raised insulin may have 356 
contributed to clearing glucose, suppressing hepatic glucose output, and opposing the potential rise 357 
in glucagon that can occur with protein feeding. Furthermore, consuming whey as a preload is 358 
known to slow gastric emptying 19. Thus, a combined influence of raised insulin concentrations 359 
prior to meal ingestion and a slower rate of gastric emptying could explain the superior influence of 360 
the preload strategy on reducing postprandial glycaemia. This explanation is supported by insulin 361 
concentrations that were similar between DUR and CON, yet glycaemia was significantly lower 362 
with DUR. Moreover, insulin concentrations were elevated with post-meal supplementation, 363 
without any improvement in glycaemia.  364 
 365 
The effects of whey protein ingestion, independent of timing of consumption, were limited to 366 
glucose and insulin responses in the current study. Postprandial lipaemia was not affected by co-367 
ingestion of whey protein with breakfast, which is in line with previous findings in normal-weight 368 
males 28 and those with and without type 2 diabetes 38, but differs from the findings of Pal et al. 39. 369 
Pal and colleagues observed a 21% reduction in plasma triglyceride AUC following 45 g whey, 370 
compared with the same dose of glucose, when administered alongside a mixed-macronutrient meal 371 
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in obese females. Such a disparity cannot be attributed to differences in fat content of test meals, as 372 
postprandial triglyceride was unaffected when relatively low (the present study) and high 38 fat test 373 
meals have been supplemented with prior whey protein. The amount of supplemental whey 374 
administered by Pal et al. however, was over 2-fold greater than both these studies, which may have 375 
influenced the observed triglyceride-lowering effect.  376 
 377 
Subjective appetite appeared to be unaffected by whey protein supplementation, regardless of 378 
condition. Prior research has demonstrated an appetite suppressing effect of whey protein, with 379 
wide ranging protocols and participants, e.g. in overweight males after a 55 g preload 40 and with a 380 
15 g whey bolus in type 2 diabetes 16. In the study by King et al. pre-meal whey protein resulted in 381 
greater post-meal insulin concentrations compared to control, possibly playing a role in appetite 382 
suppressession 41,42. However, in the current study the elevated pre-meal insulin during PRE, and 383 
the greater insulin during POST, did not translate into changes in appetite sensations. A mixed 384 
effect of whey on subjective appetite ratings in non-diabetic individuals has previously been shown. 385 
Several studies have reported reductions in appetite 43-45, although the exact mechanisms remain to 386 
be elucidated, while others show no effect on perceptions of appetite with 46,47 or without reductions 387 
in energy intake 48. Future research should explore appetite sensations and energy intake following 388 
both acute and longer term use of prandial whey protein supplementation.   389 
 390 
Whey protein at breakfast did not affect post-lunch responses across all outcomes assessed in the 391 
present study. This appears to confirm previous findings in normal-weight individuals 28, and 392 
suggests that any effects of whey protein on postprandial glycaemia are transient, and may provide 393 
rationale for researchers to investigate the supplementation of whey protein at multiple sequential 394 
meals.  395 
 396 
To the authors’ knowledge, this was the first study to assess the effect of timing of whey protein 397 
consumption on post-meal glycaemia in a non-diabetic population. The methodology was 398 
strengthened by efforts to increase the ecological validity of findings, including administering a 399 
dose of protein that could realistically be supplemented alongside a meal, and timings of 400 
supplementation that would not inconvenience individuals wishing to carry out this strategy to 401 
reduce glycaemic excursions. Care was also taken to use foods that were typical of those consumed 402 
at breakfast and lunch meals across the population. Further examination of the findings, and 403 
associated mechanisms underpinning them, is however limited. The measurement of circulating 404 
concentrations of amino acids and incretin hormones, as well as rates of gastric emptying, may have 405 
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been beneficial in this regard. Whilst the aim of the present study was to investigate the effect of 406 
whey protein supplementation and its timing, irrespective of the mechanisms of action, 407 
consideration should be given to incorporating these measures into future work.  408 
 409 
In summary, consumption of whey protein alongside a mixed-macronutrient meal attenuated 410 
postprandial glucose excursions in centrally-obese insulin resistant males. In addition, as 411 
hypothesised, consumption of whey as a preload had a similar effect on peak glucose, also 412 
attenuating glycaemia over the subsequent 3 hours, with a simultaneously reduced insulin response. 413 
Reductions in postprandial glycaemia may be beneficial in preventing or delaying the progression 414 
from normal to impaired glucose tolerance or type 2 diabetes. Postprandial lipaemia and subjective 415 
appetite, contrary to the original hypothesis, were not affected by the supplementation of 20 g whey 416 
protein or its timing of consumption. The benefits of whey supplementation are acute and future 417 
research should explore glycaemic responses and macro and micronutrient intake following long-418 
term supplementation.  419 
 420 
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FIGURE LEGENDS 576 
 577 
 578 
Figure 1. Schematic representation of experimental trials. 579 
 580 
Figure 2. Time course changes in glucose (a), insulin (c) and NEFA (e) concentrations and area 581 
under the curve for glucose (b), insulin (d) and NEFA (f) during the post-breakfast period (0-180 582 
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min). Significant differences (P < 0.05) between conditions at individual time points are defined as 583 
follows: a, PRE vs CON; b, PRE vs POST; c, DUR vs CON; black dotted line indicates time of 584 
breakfast consumption; grey dotted lines indicate time of whey protein consumption during PRE 585 
and POST conditions. Bars sharing a common symbol differ significantly from one another (P < 586 
0.05). Time course data were analysed using two-way (condition x time) repeated measures 587 
ANOVA. AUC data were analysed using one-way repeated measures ANOVA. Data are presented 588 
as mean with SEM. BL, baseline. 589 
 590 
Figure 3. Time course changes and area under the curve for combined appetite score during the 591 
post-breakfast (a-b) and post-lunch (c-d) postprandial periods. Black dotted line indicates time of 592 
breakfast consumption; grey dotted lines indicate time of whey protein consumption during PRE 593 
and POST conditions. Time course data were analysed using two-way (condition x time) repeated 594 
measures ANOVA. AUC data were analysed using one-way repeated measures ANOVA. Data are 595 
presented as mean with SEM. BL, baseline. 596 
 597 
Figure 4. Time course changes in glucose (a), insulin (c) and NEFA (e) concentrations and area 598 
under the curve for glucose (b), insulin (d) and NEFA (f) during the post-lunch period (180-360 599 
min). Time course data were analysed using two-way (condition x time) repeated measures 600 
ANOVA. AUC data were analysed using one-way repeated measures ANOVA. Data are presented 601 
as mean with SEM.  602 
 603 
Figure 5. Time course changes (a) and area under the curve (b) for plasma triglyceride 604 
concentrations throughout the full experimental protocol (0-360 min). Black dotted line indicates 605 
time of breakfast consumption; grey dotted lines indicate time of whey protein consumption during 606 
PRE and POST conditions. Time course data were analysed using two-way (condition x time) 607 
repeated measures ANOVA. AUC data were analysed using one-way repeated measures ANOVA. 608 
Data are presented as mean with SEM. BL, baseline. 609 
 610 
 611 
 612 
TABLES 613 
 614 
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 615 
Table 1. Participant characteristics (mean values with standard errors, n = 13). 616 
 Mean SEM  
Characteristics    
Age (years) 39 3  
Body mass (kg) 117.9 3.7  
Stature (cm) 181.3 2.8  
BMI (kg/m2) 36.0 1.1  
Waist circumference (cm) 121.3 2.6  
Waist/hip ratio 1.00 0.01  
Waist/height ratio 0.67 0.02  
Fasting variables    
Blood glucose (mmol/l) 5.0 0.1  
Plasma insulin (pmol/l) 122.0 24.8  
HOMA-IR 6.4 1.2  
Plasma triglyceride (mmol/l) 1.91 0.17  
 617 
Fasting values are presented as mean of fasting samples for each main trial. 618 
 619 
Table 2. Area under the curve for components of subjective appetite during post-breakfast (0-180 minutes) and post-lunch (180-360 620 
minutes) postprandial periods (mean values with standard errors, n = 13). 621 
  Area under the curve 
  PRE  DUR  POST  CON 
  Mean SEM  Mean SEM  Mean SEM  Mean SEM 
             
Hunger 
(mm x 180 min) 
Post-breakfast 6033 801  6070 911  6461 887  7641 1095 
Post-lunch 6046 734  5651 954  6378 1012  6649 929 
             
Fullness 
(mm x 180 min) 
Post-breakfast 11350 885  11553 964  11107 965  9963 1139 
Post-lunch 11347 824  11980 974  11130 1080  11003 1007 
             
PFC 
(mm x 180 min) 
Post-breakfast 7303 1034  6642 1086  7448 1094  8761 1288 
Post-lunch 7499 1069  6882 1187  7423 1165  7707 1201 
             
Satisfaction 
(mm x 180 min) 
Post-breakfast 11203 929  11194 966  10767 969  10411 982 
Post-lunch 10941 881  11548 1018  11313 979  10767 980 
              622 
PFC, prospective food consumption. AUC data were analysed using one-way repeated measures ANOVA. 623 
 624 
 625 
 626 
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